CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.
The two studies describe methods for identifying off-target mutations associated with cell-type-specific SNPs and detecting potential off-target cleavage sites.
The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
After CRISPR/Cas9 makes a double-strand break in DNA and the cell repairs it, the same set of mutations crop up again and again based on the genomic sequence.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
As the interference proceeding to resolve claims in foundational CRISPR patents draws near, Caribou has given IDT worldwide rights to sell RUO reagents.
